CN107353326B - 结合pd-1受体的非抗体结合蛋白及其应用 - Google Patents
结合pd-1受体的非抗体结合蛋白及其应用 Download PDFInfo
- Publication number
- CN107353326B CN107353326B CN201710324664.7A CN201710324664A CN107353326B CN 107353326 B CN107353326 B CN 107353326B CN 201710324664 A CN201710324664 A CN 201710324664A CN 107353326 B CN107353326 B CN 107353326B
- Authority
- CN
- China
- Prior art keywords
- cells
- nabp284
- antibody binding
- preparation
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 title claims abstract description 37
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title claims abstract description 37
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 32
- 102000014914 Carrier Proteins Human genes 0.000 title claims 10
- 210000004027 cell Anatomy 0.000 claims abstract description 97
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 33
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 230000028327 secretion Effects 0.000 claims abstract description 10
- 230000005909 tumor killing Effects 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 15
- 230000037361 pathway Effects 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 229940124622 immune-modulator drug Drugs 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 abstract description 22
- 238000002474 experimental method Methods 0.000 abstract description 18
- 210000001165 lymph node Anatomy 0.000 abstract description 11
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 9
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 9
- 210000004698 lymphocyte Anatomy 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 231100000956 nontoxicity Toxicity 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 28
- 238000012216 screening Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 10
- 238000010166 immunofluorescence Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 7
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 206010062129 Tongue neoplasm Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 201000006134 tongue cancer Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150087384 PDCD1 gene Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- AWHJQEYGWRKPHE-LSJOCFKGSA-N His-Ala-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AWHJQEYGWRKPHE-LSJOCFKGSA-N 0.000 description 1
- SWSVTNGMKBDTBM-DCAQKATOSA-N His-Gln-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SWSVTNGMKBDTBM-DCAQKATOSA-N 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- YGNUDKAPJARTEM-GUBZILKMSA-N Met-Val-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O YGNUDKAPJARTEM-GUBZILKMSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- KCIKTPHTEYBXMG-BVSLBCMMSA-N Phe-Trp-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KCIKTPHTEYBXMG-BVSLBCMMSA-N 0.000 description 1
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 1
- HRIXMVRZRGFKNQ-HJGDQZAQSA-N Pro-Thr-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HRIXMVRZRGFKNQ-HJGDQZAQSA-N 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000036326 tumor accumulation Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Description
Claims (11)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710324664.7A CN107353326B (zh) | 2017-05-09 | 2017-05-09 | 结合pd-1受体的非抗体结合蛋白及其应用 |
US16/612,455 US11014974B2 (en) | 2017-05-09 | 2017-09-06 | Non-antibody binding proteins binding to PD-1 receptors and uses thereof |
PCT/CN2017/100717 WO2018205472A1 (zh) | 2017-05-09 | 2017-09-06 | 结合pd-1受体的非抗体结合蛋白及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710324664.7A CN107353326B (zh) | 2017-05-09 | 2017-05-09 | 结合pd-1受体的非抗体结合蛋白及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107353326A CN107353326A (zh) | 2017-11-17 |
CN107353326B true CN107353326B (zh) | 2020-11-03 |
Family
ID=60271234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710324664.7A Active CN107353326B (zh) | 2017-05-09 | 2017-05-09 | 结合pd-1受体的非抗体结合蛋白及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11014974B2 (zh) |
CN (1) | CN107353326B (zh) |
WO (1) | WO2018205472A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108912212B (zh) * | 2018-06-28 | 2019-08-30 | 中山大学附属口腔医院 | 一种与cd105特异性结合的多肽及其应用 |
WO2020181402A1 (zh) * | 2019-03-10 | 2020-09-17 | 胡西木 | 一种抗肿瘤多肽及其应用 |
CN115197299A (zh) * | 2021-04-09 | 2022-10-18 | 中山大学附属口腔医院 | Pd-1受体及其配体pd-l1双靶向的非抗体结合多肽或其衍生物及其应用 |
CN113480614B (zh) * | 2021-08-13 | 2023-01-10 | 中国人民解放军总医院 | 一类靶向pd-l1的超高亲和力小蛋白及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103897036A (zh) * | 2014-03-24 | 2014-07-02 | 郑州大学 | 一种pd-1蛋白胞外段亲和肽l8及其应用 |
CN103936836A (zh) * | 2014-04-29 | 2014-07-23 | 郑州大学 | 具有抗肿瘤活性的靶向PD-L1IgV亲和肽D2 |
CN104761633A (zh) * | 2015-03-25 | 2015-07-08 | 新乡学院 | 阻断猪pd-1/pd-l1通路的多肽及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE524495T1 (de) * | 2001-07-31 | 2011-09-15 | Ono Pharmaceutical Co | Pd-1-spezifische substanz |
WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
CN105228640B (zh) | 2013-02-26 | 2018-01-16 | 王荣福 | Phf20和jmjd3组合物及其在肿瘤免疫治疗中的使用方法 |
-
2017
- 2017-05-09 CN CN201710324664.7A patent/CN107353326B/zh active Active
- 2017-09-06 US US16/612,455 patent/US11014974B2/en active Active
- 2017-09-06 WO PCT/CN2017/100717 patent/WO2018205472A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103897036A (zh) * | 2014-03-24 | 2014-07-02 | 郑州大学 | 一种pd-1蛋白胞外段亲和肽l8及其应用 |
CN103936836A (zh) * | 2014-04-29 | 2014-07-23 | 郑州大学 | 具有抗肿瘤活性的靶向PD-L1IgV亲和肽D2 |
CN104761633A (zh) * | 2015-03-25 | 2015-07-08 | 新乡学院 | 阻断猪pd-1/pd-l1通路的多肽及其应用 |
Non-Patent Citations (2)
Title |
---|
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor;Qiao Li等;《Oncotarget》;20160812;第7卷(第40期);64967-64976 * |
PD-1阻断剂在晚期肝癌治疗中的研究进展;杨梦园等;《Journal of Practical Oncology》;20170411;第32卷(第2期);184-186 * |
Also Published As
Publication number | Publication date |
---|---|
CN107353326A (zh) | 2017-11-17 |
US20200095304A1 (en) | 2020-03-26 |
WO2018205472A1 (zh) | 2018-11-15 |
US11014974B2 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107353326B (zh) | 结合pd-1受体的非抗体结合蛋白及其应用 | |
CN110330567B (zh) | 双特异性嵌合抗原受体t细胞,其制备方法和应用 | |
JP7222600B2 (ja) | 腫瘍細胞に特異的なキメラ抗原レセプター | |
CN107868791B (zh) | 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用 | |
WO2017128534A1 (zh) | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 | |
CN110684121B (zh) | 一种靶向her2联合表达pd1-mica融合蛋白的嵌合抗原受体及其表达载体和应用 | |
CN111542343A (zh) | 抗bcma的单域抗体及其应用 | |
US11246888B2 (en) | Slit2D2-chimeric antigen receptor and application thereof | |
WO2018058431A1 (zh) | 一种嵌合抗原受体分子及其应用 | |
CN108277205B (zh) | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 | |
CN112812186B (zh) | 一种抗b细胞成熟抗原的纳米抗体及其应用 | |
CN110055269B (zh) | 人间皮素嵌合抗原受体、其t细胞及其制备方法和用途 | |
CN110734498A (zh) | 一种用于解除免疫抑制的融合蛋白及其应用 | |
CN108047333B (zh) | 以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用 | |
CN112646033A (zh) | 靶向cd123的嵌合抗原受体及其用途 | |
CN112426526A (zh) | 一种nk细胞的制备方法及其在治疗癌症中的应用 | |
CN113621071A (zh) | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 | |
CN110317245B (zh) | Lag-3蛋白亲和环肽及其应用 | |
CN114315976A (zh) | 用于前列腺癌治疗的联合制剂及其医药用途 | |
WO2024056098A1 (zh) | NKG2D-NKp46细胞接合器分子及其用途 | |
CN108699163B (zh) | 一种多基因重组嵌合抗原受体分子及其应用 | |
CN116120465B (zh) | 一种靶向bcma和/或fcrh5的嵌合抗原受体及其应用 | |
WO2023115896A1 (zh) | 一种双特异性的nk细胞激动剂及制备方法和应用 | |
CN111499723B (zh) | 一种嵌合抗原受体及其应用 | |
CN112574953A (zh) | 一种间皮素嵌合抗原受体外泌体、及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230904 Address after: Room 343, 3rd Floor, No. 15 Nanwu Lane, Qiling Street, Huangpu District, Guangzhou City, Guangdong Province, 510700 (Office only) Patentee after: Guangzhou Xinpeptian Biotechnology Co.,Ltd. Address before: No. 56, Lingyuan West Road, Yuexiu District, Guangzhou, Guangdong 510055 Patentee before: ORAL SUBSIDIARY SUN YAT-SEN University Hospital Patentee before: GUANGZHOU YIDAI PHARMACEUTICAL Co.,Ltd. Effective date of registration: 20230904 Address after: 519000 Yunxi Valley Digital Industrial Park, No. 168 Youyou Road, Xiangzhou District, Zhuhai City, Guangdong Province (Block B, Meixi Commercial Plaza), 5th floor, 5-514 (centralized office area) Patentee after: Zhuhai Taisujian Biotechnology Co.,Ltd. Address before: Room 343, 3rd Floor, No. 15 Nanwu Lane, Qiling Street, Huangpu District, Guangzhou City, Guangdong Province, 510700 (Office only) Patentee before: Guangzhou Xinpeptian Biotechnology Co.,Ltd. |